Navigation Links
FDA Approves First Generic Olanzapine to Treat Schizophrenia, Bipolar Disorder

SILVER SPRING, Md., Oct. 24, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved the first generic versions of Zyprexa (olanzapine tablets) and Zyprexa Zydus (olanzapine orally disintegrating tablets) to treat schizophrenia and bipolar disorder.


Schizophrenia is a chronic, severe, and disabling brain disorder. About 1 percent of Americans have this illness. Symptoms people with schizophrenia have include: hearing voices, believing other people are reading their minds or controlling thoughts, and being suspicious or withdrawn.

Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. The symptoms of bipolar disorder include alternating periods of depression and high or irritable mood, increased activity and restlessness, racing thoughts, talking fast, impulsive behavior, and a decreased need for sleep.

"The approval of generic olanzapine offers greater access to a widely used treatment for mental illnesses," said Keith Webber, Ph.D., deputy director of the Office of Pharmaceutical Science in the FDA's Center for Drug Evaluation and Research. "Having affordable treatment options is good for patients with long-term illnesses that must be carefully managed."

Olanzapine must be dispensed with a Medication Guide that describes the risks and adverse reactions people should be mindful of when using the product. Olanzapine has a boxed warning alerting that this type of drug can raise the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). Olanzapine is not approved for treating psychosis in the elderly with dementia.

Other serious risks of olanzapine include, high blood sugar (hyperglycemia), high-lipid levels in the blood (increased cholesterol and triglycerides), and weight gain. Clinicians should take these effects into account when deciding to use this type of medication.

Generic drugs approved by FDA have the same high quality, strength, purity, and stability as brand-name drugs. The generic manufacturing, packaging, and testing sites must pass the same quality standards as those of brand name drugs.

Generic olanzapine tablets will be manufactured by Dr. Reddy's Laboratories Ltd. and Teva Pharmaceuticals USA. Generic olanzapine orally disintegrating tablets will be manufactured by Apotex Inc., Dr. Reddy's Laboratories Ltd., and Par Pharmaceuticals Inc.

For more information

FDA: Understanding Generic Drugs

National Institute of Mental Health: Schizophrenia

National Institute of Mental Health: Bipolar Disorder

Information on specific drug products, Drugs@FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Sandy Walsh, 301-796-4669,
Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Onfi To Treat Severe Type of Seizures
2. FDA Approves Longer Duration Efficacy and Safety for EUFLEXXA®
3. FDA Approves Label Update for PREZISTA® to Include 192-Week Data in HIV-1-Infected Adult Patients Starting Treatment
4. FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body
5. FDA Approves Combination Therapy Juvisync
6. FDA Approves Cialis to Treat Benign Prostatic Hyperplasia
7. FDA Approves Remicade to Treat Ulcerative Colitis in Children Older Than 6 Years
8. FDA Approves Soliris for Rare Pediatric Blood Disorder
9. FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
10. FDA Approves Xalkori with Companion Diagnostic for a Type of Late-stage Lung Cancer
11. FDA Approves Firazyr To Treat Acute Attacks of Hereditary Angioedema
Post Your Comments:
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Trovagene, ... molecular diagnostics, today announced that Chief Executive Officer Antonius ... at the 27 th Annual Piper Jaffray Healthcare ... Conference at the New York Palace Hotel in ... 2015 at 1:30 p.m. EST. Mr. Schuh will be ...
(Date:11/25/2015)... , Nov. 25, 2015 Endo International plc (NASDAQ: ... De Silva , President and CEO, will discuss corporate updates ... in New York on Wednesday, December ... . Click on Investor Relations, and then the link to ... the presentation,s start time to visit the site and download ...
(Date:11/25/2015)... 2015 Asia -based ... BioLight and the New Investors will make a direct ... a private placement. The financing will help IOPtima to ... used in the treatment of glaucoma, as well as ... IOPtimate™ system with the U.S. Food and Drug Administration, ...
Breaking Medicine Technology:
(Date:11/25/2015)... IL (PRWEB) , ... November 25, 2015 , ... On ... assets of Tri Lite’s personal heating products business. Cozy Products explains what ... personal heaters that fit in well with the Cozy Products business model: to sell ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... double board certified facial plastic surgeon specializing in both surgical and non-surgical treatments, ... The Skin Spa at Hobgood Facial Plastic Surgery. , Highly trained and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw ... and learning in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. ... For 65 years, Brillianteen has been a treasured tradition for numerous families in ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I saw a ... “I thought there had to be a convenient and comfortable way to protect them ... enables disabled individuals to safely travel during cold or inclement weather. In doing so, ...
(Date:11/25/2015)... ... 25, 2015 , ... Castlewood Treatment Center for Eating Disorders, ... as a result of the $20,000 raised at the center’s recent golf ... Club in Eureka, will help individuals who otherwise might not seek treatment for ...
Breaking Medicine News(10 mins):